文献速递炎症性肠病

克罗恩病患者皮下注射英夫利西单抗浓度阈值与黏膜愈合及透壁愈合的关系

Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-11-18

本研究为横断面研究,纳入124例接受皮下注射英夫利西单抗(SC-IFX)维持治疗≥6个月的克罗恩病患者。SC-IFX谷浓度在黏膜愈合(MH)组24.1 μg/mL vs 无MH组16.9 μg/mL(p=0.001),透壁愈合(TH)组26.0 μg/mL vs 无TH组20.5 μg/mL(p=0.007);ROC分析显示MH和TH的SC-IFX谷浓度阈值分别为17.5和30.3 μg/mL。多因素回归显示SC-IFX谷浓度与MH(OR 1.16;95%CI 1.05-1.27;p=0.002)和TH(OR 1.08;95%CI 1.02-1.14;p=0.005)显著相关。结论认为SC-IFX谷浓度与MH(≥18 μg/mL)和TH(≥30 μg/mL)正相关,可能指导治疗决策。

要点

  • SC-IFX谷浓度与MH正相关(OR 1.16;95%CI 1.05-1.27;p=0.002)。
  • SC-IFX谷浓度与TH正相关(OR 1.08;95%CI 1.02-1.14;p=0.005)。
  • MH的SC-IFX谷浓度阈值为17.5 μg/mL,TH为30.3 μg/mL。

核心结论

  • SC-IFX谷浓度与CD患者黏膜愈合(≥18 μg/mL)和透壁愈合(≥30 μg/mL)呈正相关,可能指导治疗决策以优化治疗反应。

研究设计与样本

  • 横断面研究,纳入124例接受SC-IFX维持治疗≥6个月的克罗恩病患者。

主要发现

  • MH率为77.9%(74/95),TH率为36.3%(37/102)。
  • MH组SC-IFX谷浓度24.1 μg/mL vs 无MH组16.9 μg/mL(p=0.001)。
  • TH组SC-IFX谷浓度26.0 μg/mL vs 无TH组20.5 μg/mL(p=0.007)。
  • ROC分析显示MH和TH的SC-IFX谷浓度阈值分别为17.5和30.3 μg/mL。
  • 多因素logistic回归显示SC-IFX谷浓度与MH(OR 1.16;95%CI 1.05-1.27;p=0.002)和TH(OR 1.08;95%CI 1.02-1.14;p=0.005)显著相关。

关键数值与推荐

  • MH定义为SES-CD溃疡面评分为0;TH定义为简化MaRIA评分为0。
  • MH的SC-IFX谷浓度阈值为17.5 μg/mL;TH的SC-IFX谷浓度阈值为30.3 μg/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predose trough concentrations (Ctrough) of intravenous infliximab (IV-IFX) during maintenance therapy are associated with therapeutic outcomes in patients with Crohn's disease (CD). A subcutaneous formulation of infliximab (SC-IFX) has shown high Ctrough values due to its favourable pharmacokinetics. AIMS: To evaluate the association of Ctrough of SC-IFX with therapeutic outcomes and the threshold of SC-IFX Ctrough for achieving mucosal healing (MH) and transmural healing (TH) in patients with CD. METHODS: We performed this cross-sectional study in patients with CD who had received SC-IFX maintenance therapy for ≥ 6 months. We measured SC-IFX Ctrough immediately before SC-IFX injection. We performed ileocolonoscopy/single-balloon enteroscopy and/or magnetic resonance enterography within 3 months of SC-IFX Ctrough measurement. MH was defined as SES-CD-ulcerated surface subscore of 0. TH was defined as simplified MaRIA score of 0. RESULTS: We enrolled 124 patients with MH in 77.9% (74/95) and TH in 36.3% (37/102). SC-IFX Ctrough was significantly higher in patients with MH (24.1 vs.16.9 μg/mL; p = 0.001) and TH (26.0 vs. 20.5 μg/mL; p = 0.007) than in those without. ROC analysis identified that the threshold of SC-IFX Ctrough for MH and TH were 17.5 and 30.3 μg/mL, respectively. Multivariate logistic regression showed that SC-IFX Ctrough was significantly associated with MH (OR 1.16; 95% CI 1.05-1.27; p = 0.002) and TH (OR 1.08; 95% CI 1.02-1.14; p = 0.005). CONCLUSIONS: SC-IFX Ctrough was positively associated with MH (≥ 18 μg/mL) and TH (≥ 30 μg/mL) in patients with CD, which may guide treatment decisions to optimise therapeutic response in the era of treat-to-target.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hong SN, Song JH, Kim SJ, et al. Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease. Aliment Pharmacol Ther. 2024. PMID: 39552401. doi:10.1111/apt.18354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。